Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYY-mAbs Announces Update on Omburtamab in DSRCTPREV STORYAnchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program